¾Æ¹Ð·ÎÀ̵åÁõ Ä¡·á ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Çâ, »ê¾÷ ºÐ¼® º¸°í¼­ : Ä¡·áº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° - ½ÃÀå ¿¹Ãø(2024-2032³â)
Amyloidosis Treatment Market Size, Share, Trends, Industry Analysis Report: By Treatment, End User, and Region - Market Forecast, 2024-2032
»óǰÄÚµå : 1586396
¸®¼­Ä¡»ç : Polaris Market Research
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 117 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,250 £Ü 5,908,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,250 £Ü 7,299,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ 20¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,250 £Ü 8,689,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Polaris Market ResearchÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é, ¾Æ¹Ð·ÎÀ̵åÁõ Ä¡·á ¼¼°è ½ÃÀå ±Ô¸ð´Â 2032³â±îÁö 97¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Á¶»ç º¸°í¼­´Â ÇöÀç ½ÃÀå ¿ªÇп¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÀλçÀÌÆ®¿Í ÇâÈÄ ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

¾Æ¹Ð·ÎÀ̵åÁõ Ä¡·á ½ÃÀåÀº ±¤¹üÀ§ÇÑ ÇコÄɾî Àü¸Á¿¡¼­ Áß¿äÇÑ ºÎ¹®ÀÔ´Ï´Ù. ¾Æ¹Ð·ÎÀ̵åÁõ Ä¡·á ½ÃÀåÀº ´Ù¾çÇÑ Á¶Á÷°ú Àå±â¿¡ ¾Æ¹Ð·ÎÀÌµå ´Ü¹éÁúÀÌ ºñÁ¤»óÀûÀ¸·Î Ä§ÂøµÇ´Â °ÍÀ» Ư¡À¸·Î ÇÏ´Â Èñ±ÍÇÏÁö¸¸ ½É°¢ÇÑ Áúº´±º¿¡ ´ëÇÑ Ä¡·á¹ý¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù. ¾Æ¹Ð·ÎÀ̵åÁõÀº ALÇü(°æ¼â), AAÇü(ÀÌÂ÷¼º), À¯Àü¼º, ¾ß»ýÇü ATTR(Æ®·£½º½Ç·¹Æ¾ ¾Æ¹Ð·ÎÀ̵åÁõ) µî ¿©·¯ À¯ÇüÀ¸·Î ºÐ·ùµË´Ï´Ù. ÀÌ·¯ÇÑ º´Å»ý¸®ÀÇ º¹À⼺À¸·Î ÀÎÇØ ´Ù¾çÇÑ Ä¡·á ¿É¼ÇÀÌ ÇÊ¿äÇϸç, ÀÌ´Â ½ÃÀå¿¡¼­ »ó´çÇÑ ÁøÀüÀ» °¡Á®¿Ô½À´Ï´Ù.

¾Æ¹Ð·ÎÀ̵åÁõ Ä¡·á ½ÃÀåÀº Áúº´ ¸ÞÄ¿´ÏÁò¿¡ ´ëÇÑ ±íÀº ÀÌÇØ¿Í Áø´Ü ±â¼úÀÇ Çâ»óÀ¸·Î ¼ö½Ê ³â µ¿¾È Áö¼ÓÀûÀ¸·Î ¹ßÀüÇØ ¿Ô½À´Ï´Ù. ¿ª»çÀûÀ¸·Î ¾Æ¹Ð·ÎÀ̵åÁõ Ä¡·á ¿É¼ÇÀº Á¦ÇÑÀûÀ̾ú°í, ȯÀÚÀÇ ¿¹Èİ¡ ÁÁÁö ¾ÊÀº °æ¿ì°¡ ¸¹¾Ò½À´Ï´Ù. ±×·¯³ª ´Þ¶óÅù¸¿°ú ŸÆÄ¹Ìµð½º¿Í °°Àº »õ·Î¿î Ä¡·áÁ¦ÀÇ µµÀÔÀ¸·Î ¾Æ¹Ð·ÎÀ̵åÁõ Ä¡·á¹ýÀº Å©°Ô ´Þ¶óÁ³½À´Ï´Ù.

¼¼°è ¾Æ¹Ð·ÎÀ̵åÁõ Ä¡·á ½ÃÀåÀº ÀÎ½Ä °³¼±, Áö¼ÓÀûÀÎ ¿¬±¸ °³¹ß, °í·ÉÈ­ Àα¸ Áõ°¡ µî ¿©·¯ ¿äÀÎÀ¸·Î ÀÎÇØ ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿µ»ó Áø´Ü ¹× ¹ÙÀÌ¿À¸¶Ä¿ ½Äº°°ú °°Àº Áø´Ü ±â¼úÀÇ ¹ßÀüÀº ¾Æ¹Ð·ÎÀ̵åÁõÀÇ È¿°úÀûÀÎ Ä¡·á¿¡ ÇʼöÀûÀÎ Á¶±â Áø´ÜÀ» ¿ëÀÌÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù.

¾Æ¹Ð·ÎÀ̵åÁõ Ä¡·á ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¾Æ¹Ð·ÎÀ̵åÁõ Ä¡·á ½ÃÀå¿¡¼­ ÃÖÁ¾»ç¿ëÀ» ±âÁØÀ¸·Î º¼ ¶§, ȯÀÚ Áß½É Ä¡·á¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁü¿¡ µû¶ó ȨÄÉ¾î ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È Å« ÆøÀÇ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º´¿ø ¹× Ŭ¸®´Ð ºÎ¹®Àº º¹ÀâÇÑ ¾Æ¹Ð·ÎÀ̵åÁõ »ç·Ê¸¦ ó¸®ÇÒ ¼ö ÀÖ´Â Àü¹® ÀÇ·áÁø°ú ÇÔ²² Á¾ÇÕÀûÀÎ ÀÎÇÁ¶ó¸¦ °®Ãß°í ÀÖ¾î 2023³â ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù.

Ä¡·á¹ýº°·Î´Â È­Çпä¹ý ºÐ¾ß°¡ 2023³â °ü·Ã Áúȯ, ƯÈ÷ AL ¾Æ¹Ð·ÎÀ̵åÁõ °ü¸®¿¡ ´ëÇÑ È¿´ÉÀÌ ÀÔÁõµÇ¸é¼­ È­Çпä¹ý ºÐ¾ß°¡ ½ÃÀåÀÇ ÁÖ¿ä Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ¶ÇÇÑ, º´¿ë¿ä¹ýÀÇ ¹ßÀüÀº È­Çпä¹ý¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½ÃÄ×½À´Ï´Ù.

AL ¾Æ¹Ð·ÎÀ̵åÁõ ȯÀÚ¸¦ À§ÇÑ Á¶Ç÷¸ð¼¼Æ÷ À̽Ŀ¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ÀÌ½Ä ºÐ¾ß´Â ¿¹Ãø ±â°£ µ¿¾È °ßÁ¶ÇÑ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°è ½ÃÀå¿¡¼­ ºÏ¹Ì´Â °í·ÉÈ­ Àα¸ Áõ°¡¿Í Áúº´¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡·Î ÀÎÇØ 2023³â °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀåÀº ¸¸¼ºÁúȯÀÇ Áõ°¡¿Í ÀÇ·áºñ ÁöÃâ Áõ°¡·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È Å« CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°è ÁÖ¿ä ½ÃÀå ±â¾÷À¸·Î´Â Pfizer Inc., Johnson & Johnson Services, Inc., GSK plc., Takeda Pharmaceutical Company Limited, Alnylam Pharmaceuticals, Inc., Sanofi, Merck KGaA, F. Hoffmann-La Roche Ltd, Novartis AG, Ionis Pharmaceuticals, Bristol-Myers Squibb Company, and Amgen Inc. µîÀÌ ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼Ò°³

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ¼¼°èÀÇ ¾Æ¹Ð·ÎÀ̵åÁõ Ä¡·á ½ÃÀå ÀλçÀÌÆ®

Á¦5Àå ¼¼°èÀÇ ¾Æ¹Ð·ÎÀ̵åÁõ Ä¡·á ½ÃÀå : Ä¡·áº°

Á¦6Àå ¼¼°èÀÇ ¾Æ¹Ð·ÎÀ̵åÁõ Ä¡·á ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

Á¦7Àå ¼¼°èÀÇ ¾Æ¹Ð·ÎÀ̵åÁõ Ä¡·á ½ÃÀå : Áö¿ªº°

Á¦8Àå °æÀï »óȲ

Á¦9Àå ±â¾÷ °³¿ä

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global amyloidosis treatment market size is expected to reach USD 9.79 billion by 2032, according to a new study by Polaris Market Research. The report "Amyloidosis Treatment Market Size, Share, Trends, Industry Analysis Report: By Treatment (Chemotherapy, Immunosuppressive Drugs, Transplantation, Supportive Care, Surgery, and Others), End User, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2024-2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The amyloidosis treatment market is a critical segment of the broader healthcare landscape. It focuses on therapies for a rare but serious group of diseases characterized by the abnormal deposition of amyloid proteins in various tissues and organs. Amyloidosis is categorized into several types, including AL (light chain), AA (secondary), hereditary forms, and wild-type ATTR (transthyretin amyloidosis). The complexity of these conditions necessitates a diverse array of treatment options, which has led to significant advancements in the market.

The amyloidosis treatment market has evolved continuously over the decades, driven by a deeper understanding of the disease mechanisms and improved diagnostic techniques. Historically, there were limited treatment options for amyloidosis, often resulting in poor patient outcomes. However, the recent introduction of novel therapies such as daratumumab and tafamidis has transformed the management of this condition.

The global amyloidosis treatment market is expanding due to several factors such as rising awareness, ongoing research and development, and a rising aging population. Moreover, advancements in diagnostic technologies, including imaging and biomarker identification, are facilitating earlier diagnosis, which is crucial for the effective treatment of amyloidosis.

Amyloidosis Treatment Market Report Highlights

Based on end use, the home care settings segment in the amyloidosis treatment market is expected to experience substantial growth during the forecast period due to the rising preference for patient-centered care.

The hospitals & clinics segment dominated the market in 2023 due to their comprehensive infrastructure along with specialized medical staff equipped to handle complex cases of amyloidosis.

By treatment, the chemotherapy segment accounted for a major share of the market in 2023 due to its established efficacy in managing related conditions, particularly AL amyloidosis. Moreover, advancements in combination therapies propelled the demand for chemotherapy.

The transplantation segment is projected to grow at a robust pace during the forecast period owing to the rising recognition of hematopoietic stem cell transplantation for patients affected by AL amyloidosis.

In the global market, North America accounted for the largest revenue share in 2023 due to the rising aging population and increased awareness of the disease.

The market in Asia Pacific is estimated to register a significant CAGR during the forecast period owing to the increasing prevalence of chronic diseases coupled with growing healthcare expenditure.

A few global key market players are Pfizer Inc.; Johnson & Johnson Services, Inc.; GSK plc.; Takeda Pharmaceutical Company Limited; Alnylam Pharmaceuticals, Inc.; Sanofi; Merck KGaA; F. Hoffmann-La Roche Ltd; Novartis AG; Ionis Pharmaceuticals; Bristol-Myers Squibb Company; and Amgen Inc.

Polaris Market Research has segmented the amyloidosis treatment market report based on treatment, end user, and region:

By Treatment Outlook (Revenue, USD Billion, 2024-2032)

By End User Outlook (Revenue, USD Billion, 2024-2032)

By Regional Outlook (Revenue, USD Billion, 2024-2032)

Table of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Global Amyloidosis Treatment Market Insights

5. Global Amyloidosis Treatment Market, by Treatment

6. Global Amyloidosis Treatment Market, by End-use

7. Global Amyloidosis Treatment Market, by Geography

8. Competitive Landscape

9. Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â